Physician profile
Ranjith Ramasamy
NPI 1841459252
$157,159.79
in general payments reported to CMS, 2019-2025
22 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $31K · 2021: $12K · 2022: $60K · 2023: $22K · 2024: $438 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $6,135 · Food and Beverage: $2,880 · Travel and Lodging: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,800.00 |
| Consulting Fee | $6,135.00 |
| Food and Beverage | $2,879.91 |
| Travel and Lodging | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $66,184.05 | 2019-2023 | Ams 700, Ams 700 Cxr Rte Kit |
| Coloplast Corp | $46,536.79 | 2019-2025 | Titan, Speedicath |
| Acerus Pharmaceuticals Corporation | $17,051.12 | 2020-2022 | |
| Aytu Biopharma, INC. | $11,904.93 | 2019 | |
| Endo Pharmaceuticals INC. | $10,604.64 | 2019-2024 | Xiaflex, Aveed |
| Antares Pharma, INC. | $3,340.05 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Vitrolife INC. | $263.71 | 2022 | |
| Myriad Genetic Laboratories, INC. | $239.04 | 2021-2023 | Myrisk |
| Olympus America INC. | $207.16 | 2019-2023 | Cysto-Nephro Videoscope |
| Janssen Biotech, INC. | $180.61 | 2019-2025 | Erleada |
| Axonics, INC. | $140.80 | 2022 | |
| Greenwich Biosciences, INC. | $107.12 | 2019 | |
| Intuitive Surgical, INC. | $70.85 | 2024 | |
| Abbvie INC. | $63.61 | 2024-2025 | |
| Clarus Therapeutics INC. | $62.27 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $45.50 | 2023 | |
| Rigicon,INC. | $41.78 | 2022-2023 | Rigi10 Malleable Penile Prosthesis |
| Pfizer INC. | $40.18 | 2023-2024 | |
| Tolmar, INC. | $21.40 | 2023 | |
| Sumitomo Pharma America, INC. | $19.35 | 2023 | Gemtesa |
| Tolmar Pharmaceuticals, INC. | $17.51 | 2022 | |
| Urovant Sciences INC | $17.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjith Ramasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.